American International Group, Inc. Immuneering Corp Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.91 - $7.32 $179 - $688	-94 Reduced 0.84%	11,034 $31,000
Q4 2023 Feb 13, 2024	SELL	$4.84 - $8.44 $217 - $379	-45 Reduced 0.4%	11,128 $81,000
Q3 2023 Nov 13, 2023	BUY	$7.21 - $10.68 $10,180 - $15,080	1,412 Added 14.47%	11,173 $85,000
Q2 2023 Aug 04, 2023	BUY	$6.49 - $13.36 $63,348 - $130,406	9,761 New	9,761 $98,000
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $36,690 - $73,663	-9,432 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $32,117 - $84,338	4,964 Added 111.1%	9,432 $61,000
Q4 2021 Feb 11, 2022	SELL	$16.12 - $31.02 $934 - $1,799	-58 Reduced 1.28%	4,468 $72,000
Q3 2021 Nov 12, 2021	BUY	$17.0 - $32.84 $76,942 - $148,633	4,526 New	4,526 $120,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $53.8M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.